Join to View Full Profile
201 N Congress StNewtown, PA 18940
Phone+1 215-497-7472
Dr. Hulihan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
- Drexel University College of MedicineClass of 1986
Certifications & Licensure
PA State Medical License 1988 - 2022
MN State Medical License 1990 - 1991
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 18 citationsLong-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.Heather E Olson, Sam Amin, Nadia Bahi-Buisson, Orrin Devinsky, Eric D Marsh
Epilepsia. 2024-01-01 - 8 citationsEEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper.Jeffrey Buchhalter, Caroline Neuray, Jocelyn Y Cheng, O'Neill D'Cruz, Alexandre N Datta
Epilepsy Research. 2022-11-01 - 8 citationsIntravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience.Rani K Singh, Rajdeep Singh, Alejandra Stewart, Katherine Van Poppel, Sarah Klinger
Epilepsy & Behavior Reports. 2022-01-01
Press Mentions
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021- Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
- Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
